Dare to
innovate
with us
At Brenus, we believe innovation is a collective journey. Our team brings together passionate, curious, and complementary talents to push the boundaries of science and improve patient’s lives.
Dare to innovate with us
At Brenus, we believe innovation is a collective journey. Our team brings together passionate, curious, and complementary talents to push the boundaries of science and improve patient’s lives.
Meet the team
Jacques GARDETTE
Co-founder, president
Jacques GARDETTE is a serial entrepreneur in helthcare & digital Health. He has founded 10+ companies in his career, with successful exits: 6 of these being sold to large lifescience companies such as Bard, Baxter or Nipro Healthcare in various areas from dialysis, drug delivery devices or cardiac valves. Former funder and principal shareholder of Biocorp, pioneer in innovative medicale devices, listed on Euronext Paris, now sold to Novo Nordisk for 154M€.
Benoit PINTEUR
CO-Founder & CSO
Benoit PINTEUR (PharmD) is the inventor of our platform technology, specialized in innovative therapies and a pharmaceutical development expert with experience in early R&D, QA/QC, and product development (Roche, Schering-Plough, and former founder of BioElpida aquired by Polyplus).
Paul BRAVETTI
CEO
Paul BRAVETTI (PharmD, HEC graduate) brings nearly 15 years of experience in the pharmaceutical industry (Roche, Servier, Takeda), where he successfully led the launch of innovative therapies across Europe and Asia. Since 2020, under his leadership, Brenus has raised €30M to launch a clinical trial and established partnerships with international centers of excellence.
Corinne TORTORELLI
Senior Medical Affairs & Clinical Dev. Lead
Corinne Tortorelli (PharmD, PhD) is specialized in solid tumors with an expertise in Health Management and Policy (Science Po Paris). With previous experiences at Novartis and Takeda oncology, Corinne has successfully managed product development from early clinical stages to phase III, as well as real-life clinical studies. She has also contributed to product launches in onco-hematology and rare solid tumors.
Alexander EGGERMONT
Lead Clinical Advisor
Pr Alexander EGGERMONT (MD, PhD) is chairman of the board at the Comprehensive Cancer Center München. Pr. Eggermont is the former Director General of Gustave Roussy Cancer Campus in France and was also the scientific director of the Princess Máxima Center, Utrecht. (NL). He holds key academic positions in oncology and has authored over 600 peer-reviewed publications.
Léa PERLES
Strategic Operations Lead
Léa PERLES (PharmD) is specialized in external innovation & collaboration strategy, and benefits from various experiences in academic institutions and private companies such as Sanofi. Léa has successfully negotiated and managed pharmaceutical partnership alliances across EU and led communication and management strategies.
Aymeric BORDET
Chief Financial Officer
Aymeric BORDET is an experienced CFO. He has helped health & tech companies grow from Seed to $100M in Series B funding. Passionate about finance and innovation, Aymeric was awarded the 2022 CFO Trophy by DFCG Auvergne Rhône-Alpes.
Eric DESSERTENNE
Chairman of the board
Eric DESSERTENNE (PharmD) is the Founder & CEO of Xderma. He is the former CEO of Biocorp, a connected drug delivery device company listed on Euronext (ALCOR) and acquired by Novo Nordisk. With prior experience in strategy consulting at LEK and leadership roles at Servier, Eric brings extensive expertise in MedTech innovation, IPO processes, and strategic partnerships across the life sciences sector.
Jacques GARDETTE
Co-founder, president
Jacques GARDETTE is a serial entrepreneur in helthcare & digital Health. He has founded 10+ companies in his career, with successful exits: 6 of these being sold to large lifescience companies such as Bard, Baxter or Nipro Healthcare in various areas from dialysis, drug delivery devices or cardiac valves. Former funder and principal shareholder of Biocorp, pioneer in innovative medicale devices, listed on Euronext Paris, now sold to Novo Nordisk for 154M€.
Benoit PINTEUR
CO-Founder & CSO
Benoit PINTEUR (PharmD) is the inventor of our platform technology, specialized in innovative therapies and a pharmaceutical development expert with experience in early R&D, QA/QC, and product development (Roche, Schering-Plough, and former founder of BioElpida aquired by Polyplus).
Paul BRAVETTI
CEO
Paul BRAVETTI (PharmD, HEC graduate) brings nearly 15 years of experience in the pharmaceutical industry (Roche, Servier, Takeda), where he successfully led the launch of innovative therapies across Europe and Asia. Since 2020, under his leadership, Brenus has raised €30M to launch a clinical trial and established partnerships with international centers of excellence.
Hélène SABATEL
Investment Manager
Helene SABATEL is an investment Manager at Noshaq, with a strong background in life sciences technology transfer and IP strategy. At Noshaq, actively supports and scales life sciences ventures, contributing to recent successful exits such as Vésale Pharma (LBO by Ceres Pharma), Nucleis Radiopharmaceuticals (acquired by Curium Pharma), and GQ Biotherapeutics (acquired by Pacira Bioscience). She holds a PhD in biochemistry and expertise bridging deep science and venture capital.
Marie CHAMBODUT
Partner & General Manager
Marie CHAMBODUT is a Managing Director at Angelor, with extensive experience in financial analysis, portfolio management, and private equity investments. She has driven Angelor’s recent investment in Dillico (AI-powered healthcare services) and actively contributed to strategic exits including Waga Energy (valued at €540M) and Sublimed (acquired by Laboratoires Expanscience). (With over a decade in asset management and venture capital, Marie specializes in scaling high-potential SMEs and life sciences ventures.
Diala EZZEDINE
Independant Board Member
Diala EZZEDINE (PhD) is an US-based biotech executive with 20+ years of leadership in company building, business development, and strategic growth. Currently Head of Business & Corporate Development at Magnet Biomedicine (molecular glue therapeutics) and Independent Director at Epigene Labs (AI-driven biotech). Former EVP & CBO at X-Chem Pharmaceuticals (led strategic partnerships and acquisition by PPD) and founder of Xios Therapeutics (immuno-oncology). Ph.D. in Genetics from Harvard Medical School.
Pierre DETRIXHE
Managing Partner
Pierre DETRIXHE is a Managing Partner at InvestSud. He brings over 15 years of experience in early-stage investments with a strong focus on deep tech and life sciences. He has overseen major exits including EsoBiotec (acquired for $1Bn), demonstrating a strong track record in scaling innovative biotech ventures and driving strategic value creation. His expertise spans venture capital, technology transfer, and EU-funded innovation programs, making him a key figure in high-growth technology investment.
Loïc LUCEL
Business Manager
Loïc LUCEL is an Investment Officer at UI Investissement, with expertise in financial modeling and strategic analysis for growth-stage companies. He has contributed to high-value transactions, including the $1.02Bn exit of Amolyt. Loïc brings extensive experience from roles in market research, analytics, and private equity, supporting the scaling of innovative businesses.
Laurent SACCUCCI
Investment Director
Laurent SACCUCCI is an Investment Director at Crédit Agricole Création, with strong expertise in pharma and biotech venture financing. Laurent played a key role in the $350M exit of Mablink, showcasing his experience in supporting innovative therapeutics and scaling high-potential life sciences companies.
Pr F. GHIRINGHELLI
MD, Ph.D
CGFL (FR)
Dr. François Ghiringhelli, (MD, PhD), head of the scientific board of Brenus Pharma. He is also director of the translational research center for molecular medicine at the Georges-François Leclerc Center in Dijon. Dr. Ghiringhelli is a leading expert in molecular medicine and translational research. He was recently named a laureate for the second time by the Amgen France Fund for Science and Humanity, recognizing his exceptional contributions to the field.
Pr O. J FINN
MD, Ph.D
University of Pittsburgh (US)
Pr Olivera J. Finn, (PhD) is a distinguished professor in the department of immunology, at the university of Pittsburgh School of Medicine. Dr. Finn is a pioneer in cancer immunology, known for her groundbreaking work on tumor antigens and preventive cancer vaccines. Former president of the American Association of Immunologists, she has received prestigious honors such as the AAI Lifetime Achievement Award, the AACR Lloyd Old Cancer Immunology Prize, and the SITC Richard V. Smalley Memorial Award.
Pr M. YARCHOAN
MD, Ph.D
Johns Hopkinks University (US)
Dr Mark Yarchoan, (MD) is an assistant professor of oncology, and a liver cancer specialist at Johns Hopkins Hospital, in Baltimore, where he leads research on cancer immunotherapies and co-directs the Liver Cancer Clinic. He has received honors such as the ASCO young investigator award and the Cholangiocarcinoma Foundation’s Mark R. Clements Award.
Pr I. MELERO
MD, Ph.D. Academic Hospital & CIMA of Navarra (ES)
Dr Ignacio Melero, (MD, PhD) is co-director of the department of immunology and immunotherapy, at CIMA, University of Navarra. Renowned immunologist with international experience in translational research he has held roles at Bristol Myers Squibb in the U.S. He is a key expert in cancer immunotherapy and immune mechanisms.
Pr J. TAIEB
MD, Ph.D Hospital Georges Pompidou (FR)
Pr Julien Taieb (MD, PhD) is professor at Université de Paris, head of gastroenterology and GI Oncology at Georges Pompidou Hospital. Pr. Taieb is a renowned expert in gastrointestinal oncology, particularly in colorectal and pancreatic cancers. He has led over 10 national and international Phase II/III trials and authored more than 400 scientific publications. Active in ESMO and ASCO, he also sits on the editorial board of ESMO GI Oncology, driving innovation through clinical and translational research.
Pr. A AWADA
MD, Ph.D Jules Bordet Cancer Institute (BE)
Pr Ahmad Awada (MD, PhD) is head of oncology department & director at the Chirec Cancer Institute, Brussels. Internationally recognized for his expertise in breast cancer, Pr. Awada has over 35 years of experience in oncology. He plays a key role in major societies like ASCO, ESMO, and EORTC, driving innovation in cancer treatment and research.
A ITALIANO
MD, Ph.D. Institut Bergonié and Gustave Roussy (FR)
Pr Antoine Italiano (MD, PhD) is head of early phase trials unit, at Institut Bergonié in Bordeaux, and head of precision medicine, at Gustave Roussy Cancer Institutue in Paris. Internationally recognized for his work on sarcomas and rare cancers, Pr. Italiano leads early-phase research and precision medicine initiatives. Author of 400+ publications, he is among the most cited oncology researchers.
Careers
Working at Brenus Pharma
Join a purpose-driven team where innovation, learning, and collective success shape every day.
internships
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
internships
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
internships
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
internships
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus.
September 23, 2025
Permanent position
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
Permanent position
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
Permanent position
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
Permanent position
Lorem ipsum dolor sit amet consectetur. Diam fringilla tellus diam velit eleifend dignissim. Consequat sed lectus. Copy
September 23, 2025
We are, we believe, we act
Equity
We value diversity, respect differences, and promote equal access to knowledge and opportunity
Transparency
We foster open communication, active listening, and authentic knowledge sharing
Excellence
We move forward with curiosity, rigor, and commitment to scientific progress and patient impact.
Equity
We are inclusiveWe value diversity, respect differences, and promote equal access to knowledge and opportunity
Transparency
We want clarityWe foster open communication, active listening, and authentic knowledge sharing
Excellence
We build with purposeWe move forward with curiosity, rigor, and commitment to scientific progress and patient impact.
Our talent in practice
Behind the scene and science, discover people share their roles, and what drives them at Brenus